Structure-Based Discovery of Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-Induced Osteoclastogenesis...

Area of Science:

• Biochemistry
• Pharmacology
• Drug Discovery

Background:

• Receptor activator of nuclear factor-κB ligand (RANKL) is crucial for bone resorption and a therapeutic target for osteoporosis.
• RANKL promotes osteoclast differentiation, activity, and survival, making it central to bone metabolism.

Purpose of the Study:

• To identify novel therapeutic agents targeting RANKL-induced osteoclastogenesis.
• To discover compounds with potent osteoclastogenesis inhibition and low toxicity for treating osteolytic diseases.

Main Methods:

• Employed structure-based virtual screening and experimental evaluation to identify inhibitory compounds.
• Synthesized and assessed 30 derivatives of a promising scaffold for osteoclastogenesis inhibition.
• Quantified inhibitory effects using TRAP activity and evaluated compound toxicity (LC50).

Main Results:

• Identified 11 commercially available compounds inhibiting osteoclastogenesis at low micromolar concentrations (IC50 < 5 μM).
• Three compounds demonstrated high therapeutic index with low toxicity (LC50 > 100 μM).
• Four additional derivatives showed inhibitory potential but were limited by toxicity concerns.

Conclusions:

• Discovered potent inhibitors of RANKL-induced osteoclastogenesis with diverse scaffolds.
• Identified compounds with a high therapeutic index suitable for hit-to-lead optimization.
• The findings support the development of novel therapeutics for osteolytic diseases targeting RANKL.